Lead
In September 2021, Becca Valle, then 37, sought care for severe headaches initially thought to be migraines or sinus pain; scans revealed bleeding and a brain tumor that pathologists diagnosed as glioblastoma. After two craniotomies and standard chemotherapy and radiation, Valle enrolled in a University of Maryland clinical trial that used focused ultrasound to transiently open the blood-brain barrier and permit systemic chemotherapy better access to the brain. The trial enrolled 34 participants who received between three and six ultrasound sessions over six months alongside routine imaging. Four years after her diagnosis Valle has no evidence of disease and calls herself “an outlier,” while investigators describe early signs that the method may improve survival.
Key Takeaways
- Diagnosis and timeline: Valle began severe headaches in September 2021 and, after two craniotomies, was diagnosed with glioblastoma at age 37.
- Trial size and treatment: The focused-ultrasound trial included 34 participants, each receiving three to six ultrasound sessions over roughly six months plus regular MRIs.
- Early survival signal: Investigators observed that up to 40% of trial participants were alive at an interim point when most comparable patients would typically have died.
- Standard prognosis context: MD Anderson reports about 10% of glioblastoma patients survive more than five years after diagnosis; most patients die within about 18 months.
- Safety and approvals: The University of Maryland is not yet offering the procedure outside trials because the device and method are under FDA review.
- Research implications: Trials found changes in blood-based markers after ultrasound, suggesting potential for liquid biopsies and new monitoring tools for brain cancers.
Background
Glioblastoma is the most aggressive primary brain tumor in adults and has long posed a therapeutic challenge because of the blood-brain barrier, a cellular shield that limits systemic drugs from reaching brain tissue. Standard treatment typically combines maximal safe surgical resection with radiotherapy and chemotherapy, but microscopic cancer cells often remain, driving recurrence. Historically, median survival has hovered at about a year to 18 months depending on molecular features and treatment, and only a small minority survive five years or longer; MD Anderson reports roughly 10% five-year survival.
Over the past decade researchers have explored multiple strategies to bypass or transiently disrupt the blood-brain barrier, including convection-enhanced delivery, intrathecal dosing and focused ultrasound paired with microbubbles. Focused ultrasound is minimally invasive: externally applied sound waves interact with circulating microbubbles to temporarily loosen tight junctions in capillaries, increasing permeability for hours. Early work in animals and small human studies suggested the technique can be applied repeatedly with a favorable safety profile, prompting multi-institutional trials in patients with primary brain cancers and metastases.
Main Event
Valle first sought medical help when headaches escalated to vomiting and inability to sit up; an emergency scan showed intracranial bleeding, prompting an exploratory craniotomy and subsequent tumor resection. Pathology confirmed glioblastoma, and she received adjuvant chemoradiation as is standard. Given the tumor type’s grim prognosis, her care team discussed clinical trial options and offered a study testing focused ultrasound to open the blood-brain barrier during systemic chemotherapy.
Dr. Graeme Woodworth, the trial’s lead investigator and chief of neurosurgery at the University of Maryland Medical Center, described the protocol as using focused ultrasound together with commercially available microbubble contrast agents to induce a short-lived opening in capillary walls. Each participant wore a head device during sessions; treatments were spaced across months with frequent MRI surveillance to watch for recurrence or adverse effects. Valle said agreeing to join was straightforward: she saw potential life-saving benefit.
Investigators later compared the trial participants to a larger contemporary matched control group who had received standard adjuvant chemotherapy without the ultrasound intervention. Woodworth reported an early survival advantage in the trial cohort: at an interim follow-up point, about 40% of treated patients remained alive at a time when investigators expected most would have progressed. The study team cautioned that tracking of drug concentration within tumors was not performed in real time, and follow-up analyses were needed.
Analysis & Implications
The most immediate implication is that transiently opening the blood-brain barrier can be performed safely in the context of repeated sessions and frequent imaging, at least within the limits of this early study. Safety is a critical threshold because even brief openings could, in theory, permit harmful inflammation, infection risk or vascular injury; the reported protocol included careful monitoring and found no widespread acute complications in Valle’s experience. That safety signal supports larger, more rigorous evaluations.
From an efficacy standpoint, the observed survival difference is a noteworthy signal but not definitive proof. The study used a contemporary matched control group rather than a randomized control; matched comparisons can reduce bias but remain susceptible to unmeasured differences between groups. Experts such as Dr. Patrick Wen have said the results represent an encouraging step and urged subsequent trials to randomize patients and test different chemotherapy agents to refine benefit estimates.
If larger randomized studies confirm a meaningful survival or progression-free survival benefit, the technique could reshape the drug-development landscape for brain disorders by allowing established and novel systemic therapies to reach intracranial targets. That would also spur pharmaceutical and biotech interest in combination regimens tailored to penetrate the central nervous system. Regulatory approval and device availability remain gating steps: an FDA-cleared, clinic-ready system would be required before broad adoption.
Comparison & Data
| Metric | Typical glioblastoma outcomes | Trial cohort (interim) |
|---|---|---|
| 5‑year survival | ~10% (MD Anderson) | Not established; interim data suggest higher-than-expected survival at specific follow-up points (up to 40% alive) |
| Usual median survival | ~12–18 months | Not yet mature; investigators report survival advantage versus matched controls |
The table highlights why caution is necessary: the trial’s up-to-40% figure refers to an interim follow-up and is not equivalent to a validated five-year survival rate. Contextualizing early signals against historic benchmarks helps readers understand potential, but it does not replace randomized evidence or longer-term follow-up.
Reactions & Quotes
“It was a no-brainer. This could save my life.”
Becca Valle, trial participant
Valle framed enrollment as a clear choice given glioblastoma’s prognosis and the study’s potential to enhance drug delivery to the brain. Her experience of no reported trial-related side effects and current absence of disease are central to the human story behind the data.
“We saw up to 40% of the patients in the study were still alive at a time we expected most would have succumbed to progressive brain cancer.”
Dr. Graeme Woodworth, University of Maryland (lead investigator)
Woodworth emphasized that drug tracking within tumors was not available during the study and that follow-up data informed the survival observation. He also noted ongoing efforts to expand and confirm the findings in additional trials and regulatory submissions.
“An important step in the right direction,”
Dr. Patrick Wen, Dana-Farber Cancer Institute (outside expert)
Wen called the results encouraging but recommended randomized designs and exploration of different chemotherapy agents to better define the technology’s clinical value.
Unconfirmed
- The durability of the trial’s apparent survival advantage beyond the reported interim follow-up is not yet established.
- Direct measurements of chemotherapy concentration inside human tumors during the trial were not available at the time of reporting.
- Whether the benefit observed in this cohort will generalize across different chemotherapy agents, tumor molecular subtypes or broader patient populations remains to be proven.
- The timeline for FDA review and potential wider clinical availability of a cleared device is uncertain.
Bottom Line
Becca Valle’s case illustrates both the promise and the limits of early-stage innovation in neuro-oncology: she is a striking example of long-term survival after glioblastoma and participation in a focused-ultrasound trial, but her outcome alone cannot establish the new approach as standard of care. The study led by University of Maryland investigators produced an encouraging survival signal and a reassuring safety profile in a 34-patient cohort, but the data are interim and derived from matched comparisons rather than randomized assignment.
If ongoing and future randomized trials corroborate these findings, focused ultrasound to open the blood-brain barrier could become a pivotal tool to improve delivery of systemic therapies to brain tumors and spur combination research. For now, the technique remains investigational, requiring further validation, regulatory review and consensus on optimal drug-device pairings before broad clinical use.
Sources
- CBS News — original report and patient interview (media)
- MD Anderson Cancer Center — glioblastoma statistics and prognosis (academic/clinical)
- University of Maryland Medical Center — trial leadership and institutional information (institutional)
- Dana-Farber Cancer Institute — expert commentary (academic/clinical)